Literature DB >> 23339625

Time-dependent changes in hepatic and intestinal induction of cytochrome P450 3A after administration of dexamethasone to rats.

Kazunori Iwanaga1, Tatsuya Honjo, Makoto Miyazaki, Masawo Kakemi.   

Abstract

We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration. On the other hand, a mild increase of CYP3A activity, which lasted for at least 48 h, was observed in both tissues after administration of multiple doses. Some physiological compounds such as cytokines might be involved in decreasing the CYP3A activity to maintain homeostasis of the body.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23339625     DOI: 10.3109/00498254.2012.761741

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  4 in total

1.  Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer.

Authors:  Jian Li; Qing-Yu Yao; Jun-Sheng Xue; Li-Jie Wang; Yin Yuan; Xiu-Yun Tian; Hong Su; Si-Yuan Wang; Wen-Jun Chen; Wei Lu; Tian-Yan Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-06-26       Impact factor: 6.150

2.  Time-dependent pharmacokinetics of dexamethasone and its efficacy in human breast cancer xenograft mice: a semi-mechanism-based pharmacokinetic/pharmacodynamic model.

Authors:  Jian Li; Rong Chen; Qing-Yu Yao; Sheng-Jun Liu; Xiu-Yun Tian; Chun-Yi Hao; Wei Lu; Tian-Yan Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-11-09       Impact factor: 6.150

3.  Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Authors:  Marzia A Locatelli; Philippe Aftimos; E Claire Dees; Patricia M LoRusso; Mark D Pegram; Ahmad Awada; Bo Huang; Rossano Cesari; Yuqiu Jiang; M Naveed Shaik; Kenneth A Kern; Giuseppe Curigliano
Journal:  Oncotarget       Date:  2017-01-10

4.  Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators.

Authors:  Sanjita Paudel; Aarajana Shrestha; Piljoung Cho; Riya Shrestha; Younah Kim; Taeho Lee; Ju-Hyun Kim; Tae Cheon Jeong; Eung-Seok Lee; Sangkyu Lee
Journal:  Pharmaceutics       Date:  2019-09-16       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.